Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Sunshine Biopharma (SBFM) EBIAT (2016 - 2026)

Sunshine Biopharma filings provide 14 years of EBIAT readings, the most recent being -$2.1 million for Q4 2025.

  • On a quarterly basis, EBIAT rose 0.8% to -$2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$6.0 million, a 16.39% decrease, with the full-year FY2025 number at -$6.0 million, down 16.39% from a year prior.
  • EBIAT hit -$2.1 million in Q4 2025 for Sunshine Biopharma, down from -$883820.0 in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $667116.0 in Q4 2021 to a low of -$23.5 million in Q4 2022.
  • Median EBIAT over the past 5 years was -$1.3 million (2023), compared with a mean of -$2.7 million.
  • The widest YoY moves for EBIAT: up 161.55% in 2021, down 6461.84% in 2021.
  • Sunshine Biopharma's EBIAT stood at $667116.0 in 2021, then plummeted by 3624.47% to -$23.5 million in 2022, then surged by 94.68% to -$1.3 million in 2023, then tumbled by 72.65% to -$2.2 million in 2024, then grew by 0.8% to -$2.1 million in 2025.
  • The last three reported values for EBIAT were -$2.1 million (Q4 2025), -$883820.0 (Q3 2025), and -$1.8 million (Q2 2025) per Business Quant data.